










A**B****C****D****E**

A**B****C****D****E**

A

Implant 293-Oligo-
IL13-PE/WT + GBM-
dsLuc-Rluc

Daily Fluc + Rluc imaging →


d0

d1


d2




B







G136-IL13Rα2

**C**

U251










A

LV-IL13-Gluc-PE

**B**IL13-Gluc-PE secretion *in vitro***C**IL13-Gluc-PE conditioned medium *in vivo***D**Cells secreting IL13-Gluc-PE encapsulated in sECM *in vivo*

A**GBM modifications do not affect their response to IL13-PE**